Oxysterols and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11117924-B2
Application number	US-201615742424-A
Country	US
Kind code	B2
Filing date	Jul 6, 2016
Priority date	Jul 6, 2015
Publication date	Sep 14, 2021
Grant date	Sep 14, 2021

Abstract

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R 1 , R 2 , and R 3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

First claim

What is claimed is:

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is substituted or unsubstituted C 1-6 alkyl;
R 2 is selected from the group consisting of cyclobutyl, cyclopentyl, and cyclohexyl;
R 5 is absent or hydrogen; and
represents a single or double bond, wherein when one is a double bond, the other is a single bond and R 5 is absent.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is substituted C 1-6 alkyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted C 1-6 alkyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is methyl or ethyl.

5. The compound of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-A) or Formula (I-B):

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound of Formula (I) is selected from:

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. A method of inducing sedation or anesthesia comprising administering to a subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof.

Assignees

• Sage Therapeutics Inc

Inventors

• Salituro Francesco G
• Robichaud Albert Jean
• Martinez Botella Gabriel
• Harrison Boyd L

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title